Evidence Corner
Welcome to Evidence Corner. Here we try to explain the data behind the clinical decisions we make through deep-diving studies that have shaped how we treat patients with liver disease. For each clinical question, we’ve chosen a single study and with our digestible slides, we try to concisely highlight the key aspects of the study.
Series Team
Fellow Lead
Faculty Editor
Evidence CornerShould patients with alcohol-associated hepatitis be treated with NAC in addition to prednisolone?
Some people treat alcohol-associated hepatitis with both NAC and prednisolone and some with just prednisolone- here is the trial that underlies this decision: https://www.nejm.org/doi/full/10.1056/nejmoa1101214
Alex VogelEvidence CornerIs liver transplantation a viable treatment for intrahepatic cholangiocarcinoma?
Can liver transplantation be an effective therapy for intrahepatic cholangiocarcinoma?
Jennifer WangEvidence CornerShould patients with clinically significant portal hypertension be on beta-blockers?
Can beta-blockade in patients with clinically significant portal hypertension prevent decompensations? The PREDESCI trial sought out to determine just that!
Lizzie AbyEvidence CornerIs Semaglutide the treatment for NASH we’ve been waiting for?
Effective treatments for NASH have been elusive. Is Semaglutide the answer people have been waiting for?
Jennifer WangEvidence CornerIs obeticholic acid effective in patients with PBC?
Is obeticholic acid effective in the treatment of patients with PBC?
Lizzie AbyEvidence CornerWhat is the best systemic therapy for unresectable HCC?
In patients with unresectable HCC, what is the best systemic therapy? https://www.nejm.org/doi/full/10.1056/NEJMoa1915745
Alex VogelEvidence CornerPredicting steroid responsiveness in patients with severe alcohol-associated hepatitis
Ever wondered why we calculate a Lille score in patients being treated for alcohol-associated hepatitis with prednisolone? This is the Evidence Corner for you!
Lizzie AbyEvidence CornerActivated CD8 T-cell Hepatitis in Children with Indeterminate Acute Liver Failure
What new condition should be considered and worked up in patients with pediatric acute liver failure of unknown origin?
Tamir DiamondEvidence CornerDoes the addition of rifaximin to lactulose improve outcomes in overt hepatic encephalopathy?
A review of the study on rifaximin as an adjunctive therapy in treatment of hepatic encephalopathy.
Lizzie AbyEvidence CornerIs PEG as good as lactulose for treating inpatients with hepatic encephalopathy?
Can polyethylene glycol (PEG) be used to treat hepatic encephalopathy in hospitalized patients?
Alex VogelSeries Team
Fellow Lead
Faculty Editor
Ideas?
Do you have suggestions for topics within this series? Are you a fellow interested in contributing? Please feel free to reach out via Twitter to the fellow lead or to Liver Fellow Network directly. You can also e-mail us at liverfellownetwork@gmail.com.